BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





 Company News
FDA Approves Bristol-Myers Squibb Company (BMY)’s Evotaz™ (Atazanavir And Cobicistat) For The Treatment Of HIV-1 Infection In Adults 1/30/2015 6:06:45 AM
FDA Green Lights Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ) HIV Pills 1/30/2015 6:03:28 AM
Celldex Therapeutics, Inc. (CLDX) And Bristol-Myers Squibb Company (BMY) Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors 1/29/2015 7:36:47 AM
Diagnostics For All Appoints Fran Heller, Former Bristol-Myers Squibb Company (BMY) Senior Executive, To Board Of Directors 1/26/2015 7:38:40 AM
Bristol-Myers Squibb Company (BMY) Names Caforio As New CEO Effective May 5 1/20/2015 3:59:29 PM
J.P. Morgan: Five Prime Therapeutics, Inc. (FPRX) CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company (BMY) 1/15/2015 1:19:13 PM
Bristol-Myers Squibb Company (BMY) And Eli Lilly (LLY) Enter Clinical Collaboration Agreement To Evaluate Opdivo (Nivolumab) In Combination With Galunisertib In Advanced Solid Tumors 1/13/2015 7:34:32 AM
Bristol-Myers Squibb Company (BMY) Release: CheckMate -017, A Phase 3 Study Of Opdivo (Nivolumab) Compared To Docetaxel In Patients With Second-Line Squamous Cell Non-Small Cell Lung Cancer, Stopped Early 1/12/2015 2:41:08 PM
Seattle Genetics, Inc. (SGEN) And Bristol-Myers Squibb Company (BMY) Announce Clinical Collaboration To Evaluate Combination Of Adcetris® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Hematologic Malignancies 1/12/2015 11:20:12 AM
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/12/2015 5:59:50 AM
12345678910...